oxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4

Chen,Yuan; Wang,Zhiyi; Li,Qian; Yu,Lichun; Zhu,Yanji; Wang,Jing; Sun,Shuzhen

doi:10.3892/mmr.2020.11292

oxLDL promotes podocyte migration by regulating CXCL16, ADAM10 and ACTN4

Authors:
- Yuan Chen
- Zhiyi Wang
- Qian Li
- Lichun Yu
- Yanji Zhu
- Jing Wang
- Shuzhen Sun
View Affiliations

Affiliations: Department of Pediatrics, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250021, P.R. China, Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China, Department of Pediatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China, Department of Pediatrics, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China
Published online on: June 30, 2020 https://doi.org/10.3892/mmr.2020.11292
Pages: 1976-1984
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nephrotic syndrome (NS) is one of the most common causes of chronic kidney disease in the pediatric population. Hyperlipidemia is one of the main features of NS. The present study investigated the role of CXC motif chemokine ligand 16 (CXCL16) and ADAM metallopeptidase domain 10 (ADAM10) in oxidized low‑density lipoprotein (oxLDL)‑stimualted podocytes and the underlying mechanisms. CXCL16 and ADAM10 expression levels in oxLDL‑treated podocytes were measured via reverse transcription‑quantitative PCR and western blotting. Cell migration assays were conducted to assess the migration of oxLDL‑treated podocytes. CXCL16 or ADAM10 overexpression and knockdown assays were conducted. The results indicated that oxLDL stimulation increased ADAM10 and CXCL16 expression levels, and enhanced podocyte migration compared with the control group. Moreover, CXCL16 and ADAM10 overexpression significantly increased podocyte migration and the expression of actinin‑α4 (ACTN4) compared with the control groups. By contrast, CXCL16 and ADAM10 knockdown significantly reduced podocyte migration and the expression of ACTN4 compared with the control groups. The results suggested that oxLDL promoted podocyte migration by regulating CXCL16 and ADAM10 expression, as well as by modulating the actin cytoskeleton. Therefore, CXCL16 and ADAM10 may serve as novel therapeutic targets for primary nephrotic syndrome in children.

View Figures

View References

1	McCaffrey J, Lennon R and Webb NJ: The non-immunosuppressive management of childhood nephrotic syndrome. Pediatr Nephrol. 31:1383–1402. 2016. View Article : Google Scholar : PubMed/NCBI
2	Zhao X, Hwang DY and Kao HY: The role of glucocorticoid receptors in podocytes and nephrotic syndrome. Nucl Receptor Res. 5:52018. View Article : Google Scholar
3	Ranganathan S: Pathology of podocytopathies causing nephrotic syndrome in children. Front Pediatr. 4:322016. View Article : Google Scholar : PubMed/NCBI
4	Fornoni A, Merscher S and Kopp JB: Lipid biology of the podocyte - new perspectives offer new opportunities. Nat Rev Nephrol. 10:379–388. 2014. View Article : Google Scholar : PubMed/NCBI
5	Hu M, Fan M, Zhen J, Lin J, Wang Q, Lv Z and Wang R: FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDL. J Cell Mol Med. 21:552–567. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mertens A and Holvoet P: Oxidized LDL and HDL: Antagonists in atherothrombosis. FASEB J. 15:2073–2084. 2001. View Article : Google Scholar : PubMed/NCBI
7	Zhang F, Wang C, Wang H, Lu M, Li Y, Feng H, Lin J, Yuan Z and Wang X: Ox-LDL promotes migration and adhesion of bone marrow-derived mesenchymal stem cells via regulation of MCP-1 expression. Mediators Inflamm. 2013:6910232013. View Article : Google Scholar : PubMed/NCBI
8	Rubina K, Talovskaya E, Cherenkov V, Ivanov D, Stambolsky D, Storozhevykh T, Pinelis V, Shevelev A, Parfyonova Y, Resink T, et al: LDL induces intracellular signalling and cell migration via atypical LDL-binding protein T-cadherin. Mol Cell Biochem. 273:33–41. 2005. View Article : Google Scholar : PubMed/NCBI
9	Liang H, Liao M, Zhao W, Zheng X, Xu F, Wang H and Huang J: CXCL16/ROCK1 signaling pathway exacerbates acute kidney injury induced by ischemia-reperfusion. Biomed Pharmacother. 98:347–356. 2018. View Article : Google Scholar : PubMed/NCBI
10	Kato T, Hagiyama M and Ito A: Renal ADAM10 and 17: Their physiological and medical meanings. Front Cell Dev Biol. 6:1532018. View Article : Google Scholar : PubMed/NCBI
11	Hu ZB, Chen Y, Gong YX, Gao M, Zhang Y, Wang GH, Tang RN, Liu H, Liu BC and Ma KL: Activation of the CXCL16/CXCR6 pathway by inflammation contributes to atherosclerosis in patients with end-stage renal disease. Int J Med Sci. 13:858–867. 2016. View Article : Google Scholar : PubMed/NCBI
12	Fang Y, Henderson FC Jr, Yi Q, Lei Q, Li Y and Chen N: Chemokine CXCL16 expression suppresses migration and invasiveness and induces apoptosis in breast cancer cells. Mediators Inflamm. 2014:4786412014. View Article : Google Scholar : PubMed/NCBI
13	Garcia GE, Truong LD, Li P, Zhang P, Johnson RJ, Wilson CB and Feng L: Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol. 170:1485–1496. 2007. View Article : Google Scholar : PubMed/NCBI
14	Schramme A, Abdel-Bakky MS, Gutwein P, Obermüller N, Baer PC, Hauser IA, Ludwig A, Gauer S, Schäfer L, Sobkowiak E, et al: Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int. 74:328–338. 2008. View Article : Google Scholar : PubMed/NCBI
15	Gutwein P, Abdel-Bakky MS, Schramme A, Doberstein K, Kämpfer-Kolb N, Amann K, Hauser IA, Obermüller N, Bartel C, Abdel-Aziz AA, et al: CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol. 174:2061–2072. 2009. View Article : Google Scholar : PubMed/NCBI
16	Schramme A, Abdel-Bakky MS, Kämpfer-Kolb N, Pfeilschifter J and Gutwein P: The role of CXCL16 and its processing metalloproteinases ADAM10 and ADAM17 in the proliferation and migration of human mesangial cells. Biochem Biophys Res Commun. 370:311–316. 2008. View Article : Google Scholar : PubMed/NCBI
17	Wang L, Sun S, Zhou A, Yao X and Wang Y: oxLDL-induced lipid accumulation in glomerular podocytes: Role of IFN-γ, CXCL16, and ADAM10. Cell Biochem Biophys. 70:529–538. 2014. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Davin JC: The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol. 31:207–215. 2016. View Article : Google Scholar : PubMed/NCBI
20	Kalluri R: Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol. 17:2383–2389. 2006. View Article : Google Scholar : PubMed/NCBI
21	Assady S, Wanner N, Skorecki KL and Huber TB: New insights into podocyte biology in glomerular health and disease. J Am Soc Nephrol. 28:1707–1715. 2017. View Article : Google Scholar : PubMed/NCBI
22	Reiser J and Altintas M: Podocytes. F1000Res. 5:1142016. View Article : Google Scholar
23	Tan X, Chen Y, Liang X, Yu C, Lai Y, Zhang L, Zhao X, Zhang H, Lin T, Li R, et al: Lipopolysaccharide-induced podocyte injury is mediated by suppression of autophagy. Mol Med Rep. 14:811–818. 2016. View Article : Google Scholar : PubMed/NCBI
24	Greka A and Mundel P: Cell biology and pathology of podocytes. Annu Rev Physiol. 74:299–323. 2012. View Article : Google Scholar : PubMed/NCBI
25	Lin T, Zhang L, Liu S, Chen Y, Zhang H, Zhao X, Li R, Zhang Q, Liao R, Huang Z, et al: WWC1 promotes podocyte survival via stabilizing slit diaphragm protein dendrin. Mol Med Rep. 16:8685–8690. 2017. View Article : Google Scholar : PubMed/NCBI
26	Akchurin O and Reidy KJ: Genetic causes of proteinuria and nephrotic syndrome: Impact on podocyte pathobiology. Pediatr Nephrol. 30:221–233. 2015. View Article : Google Scholar : PubMed/NCBI
27	Yu SM, Nissaisorakarn P, Husain I and Jim B: Proteinuric kidney diseases: A Podocyte's slit diaphragm and cytoskeleton approach. Front Med (Lausanne). 5:2212018. View Article : Google Scholar : PubMed/NCBI
28	Vallon V and Komers R: Pathophysiology of the diabetic kidney. Compr Physiol. 1:1175–1232. 2011.PubMed/NCBI
29	Noris M and Remuzzi G: Non-muscle myosins and the podocyte. Clin Kidney J. 5:94–101. 2012. View Article : Google Scholar : PubMed/NCBI
30	Jin X, Wang W, Mao J, Shen H, Fu H, Wang X, Gu W, Liu A, Yu H, Shu Q, et al: Overexpression of Myo1e in mouse podocytes enhances cellular endocytosis, migration, and adhesion. J Cell Biochem. 115:410–419. 2014. View Article : Google Scholar : PubMed/NCBI
31	Kistler AD, Altintas MM and Reiser J: Podocyte GTPases regulate kidney filter dynamics. Kidney Int. 81:1053–1055. 2012. View Article : Google Scholar : PubMed/NCBI
32	Cechova S, Dong F, Chan F, Kelley MJ, Ruiz P and Le TH: MYH9 E1841K mutation augments proteinuria and podocyte injury and migration. J Am Soc Nephrol. 29:155–167. 2018. View Article : Google Scholar : PubMed/NCBI
33	Shao H, Wang JH, Pollak MR and Wells A: α-actinin-4 is essential for maintaining the spreading, motility and contractility of fibroblasts. PLoS One. 5:e139212010. View Article : Google Scholar : PubMed/NCBI
34	Duning K, Schurek EM, Schlüter M, Bayer M, Reinhardt HC, Schwab A, Schaefer L, Benzing T, Schermer B, Saleem MA, et al: KIBRA modulates directional migration of podocytes. J Am Soc Nephrol. 19:1891–1903. 2008. View Article : Google Scholar : PubMed/NCBI
35	Fernández D, Horrillo A, Alquezar C, González-Manchón C, Parrilla R and Ayuso MS: Control of cell adhesion and migration by podocalyxin. Implication of Rac1 and Cdc42. Biochem Biophys Res Commun. 432:302–307. 2013. View Article : Google Scholar : PubMed/NCBI
36	Mundel P and Reiser J: Proteinuria: An enzymatic disease of the podocyte? Kidney Int. 77:571–580. 2010. View Article : Google Scholar : PubMed/NCBI
37	Li Z, Zhang L, Shi W, Chen Y, Zhang H, Liu S, Liang X, Ling T, Yu C, Huang Z, et al: Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions. Mol Med Rep. 12:6849–6854. 2015. View Article : Google Scholar : PubMed/NCBI
38	Shao H, Travers T, Camacho CJ and Wells A: The carboxyl tail of alpha-actinin-4 regulates its susceptibility to m-calpain and thus functions in cell migration and spreading. Int J Biochem Cell Biol. 45:1051–1063. 2013. View Article : Google Scholar : PubMed/NCBI
39	Michaud JL, Chaisson KM, Parks RJ and Kennedy CR: FSGS-associated alpha-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes. Kidney Int. 70:1054–1061. 2006. View Article : Google Scholar : PubMed/NCBI
40	Feng D, DuMontier C and Pollak MR: The role of alpha-actinin-4 in human kidney disease. Cell Biosci. 5:442015. View Article : Google Scholar : PubMed/NCBI
41	Wang P, Zhao F, Nie X, Liu J and Yu Z: Knockdown of NUP160 inhibits cell proliferation, induces apoptosis, autophagy and cell migration, and alters the expression and localization of podocyte associated molecules in mouse podocytes. Gene. 664:12–21. 2018. View Article : Google Scholar : PubMed/NCBI